The Role of Platelet TLRs in Platelet Activation During VTE
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 44 people enrolled
- Started
- 11 Oct 2023
- Ended
- 10 Oct 2025
- Type of study
- Observational
- Treatments tested
- blood sample
- Record updated
- 8 May 2026
- Why it stopped
- Challenges in inclusion
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients diagnosed with Venous ThromboEmbolic (VTE) / Proximal Deep vein thrombosis (DVT) of the lower limb and/or pulmonary embolism ≤ 72heures
- Patients are 18 years of age or older at diagnosis
- Patients received informed written consent
- Patients benefiting from social security coverage
Who cannot take part
- Patients on non-steroidal anti-inflammatory drugs (NSAIDs)
- Diagnosis of Venous ThromboEmbolic (VTE) more than 72 hours old
- Isolated sub-segmental pulmonary embolism
- Patients on antiplatelet agents
- Life expectancy > 3 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Venous thromboembolic disease (VTE) is a frequent and potentially serious pathology. Therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated French management recommendations.
Read full original descriptionShow less
One of the main remaining difficulties concerns VTE sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. The mechanisms leading to the absence of complete repermeabilization of vessels affected by Venous thromboembolic disease (VTE) are still poorly understood.
The concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. Platelets appear to play a key role in the onset of sequelae: Platelets are known to be involved both in the onset of a VTE episode and in the inflammatory response. This involvement is illustrated by the expression of inflammatory receptors such as TLR (toll-like receptor) 2 and TLR4.
Th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in Venous thromboembolic disease (VTE) patients.
The group in the trial
- Venous ThromboEmbolic (VTE) patients
a diagnosis of Venous ThromboEmbolic (VTE) less than 72 hours old at inclusion, with a follow-up of 3 to 6 months
Treatment: blood sample
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 8 May 2026